Predicting Response to Vedolizumab in Anti-TNF Refractory IBD Patients Using PIMS® Technology
Abstract Background Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, is a chronic condition that significantly impacts patients’ quality of life. While biologic therapies like anti-TNF agents have revolutionized treatment, a substantial proportion of patients do not respond to these therapies. Vedolizumab, an anti-integrin antibody, offers an alternative for patients refractory to anti-TNF […]
How to identify Hydroxychloroquine’s ON and OFF targets to design a more potent molecule with enhanced clinical efficacy and reduced retinal toxicity in comparison to HCQ?
Description
Evodiamine as a Macrophage Cholesterol Efflux Enhancer: Interactome Analysis Reveals ABCA1 to be a Direct Binding Target
Isolation of Clozapine targets from rat brain total homogenates
Description
Functional molecular network analysis enables prediction of response to vedolizumab therapy in anti-TNF refractory IBD patients
